Weight Management
Research compounds for weight and body-composition work that fits your actual application.
Semaglutide and Weight Loss: What the Research Actually Showed
If you have tried to lose weight and watched the scale do its own thing, you have probably been told to eat less and move more. That is downstream advice. Semaglutide works upstream, at the hormone signal that tells your brain you are full. Here is what the 68-week trial showed — no jargon, no hype.
Tirzepatide: What the SURMOUNT-1 Trial Actually Showed
A dual GIP/GLP-1 receptor agonist produced some of the largest weight-loss results ever reported in a controlled obesity trial. Here is what the study found — no jargon, no hype, just what the data show.
The 15% Number: What the Scale Actually Showed
The headline result from the semaglutide trial is the magnitude of weight loss. Here is what was actually measured, in plain English.
The 22.5% Number: What the Magnitude Actually Means
The single most-cited result from SURMOUNT-1 is the size of the weight loss at the highest studied dose. Here is what was actually measured, in plain English.
Holding the Line: Why the Weight Stayed Off
The semaglutide weight loss was not a peak-and-crash. The majority of the loss was sustained through the 68-week treatment window. Here is what that does and does not mean.
Dose Ordering: Why More Studied Input Meant More Loss
Weight loss in SURMOUNT-1 increased with the studied dose — higher doses produced greater mean loss than lower. Here is what that does and does not tell you.
Crossing Thresholds: Who Hit the Big Targets
More semaglutide participants crossed 5%, 10%, and 15% weight-loss thresholds than placebo. Here is what that does and does not tell you, in plain English.
The 20% Threshold: How Many Responded Big
A substantial share of participants at the higher studied doses reached 20% or more weight loss. Here is what that does and does not mean, in plain English.
The GI Story: What the Side-Effect Data Showed
Gastrointestinal effects were the most common adverse events in the semaglutide trial. Here is exactly how that is — and is not — a tolerability claim.
The Safety Story: Gastrointestinal Effects and What They Mean
Gastrointestinal effects were the most common adverse events in SURMOUNT-1, mostly easing over time. Here is exactly how that is — and is not — a safety claim.
Have a question about your work?
Talk it through with a research specialist — private, written, no commitment.